Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.

Lieu CH, Golemis EA, Serebriiskii IG, Newberg JY, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton GM, Cooke M, Meyer JE.

Clin Cancer Res. 2019 Jun 26. pii: clincanres.0899.2019. doi: 10.1158/1078-0432.CCR-19-0899. [Epub ahead of print]

PMID:
31243121
2.

Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs.

Kiseleva AA, Korobeynikov VA, Nikonova AS, Zhang P, Makhov P, Deneka AY, Einarson MB, Serebriiskii IG, Liu H, Peterson JR, Golemis EA.

Clin Cancer Res. 2019 Jul 1;25(13):4179-4193. doi: 10.1158/1078-0432.CCR-18-3535. Epub 2019 Mar 13.

PMID:
30867219
3.

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.

Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B.

Clin Cancer Res. 2019 Jun 1;25(11):3430-3442. doi: 10.1158/1078-0432.CCR-18-0440. Epub 2019 Feb 12.

4.

Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma.

Nicolas E, Demidova EV, Iqbal W, Serebriiskii IG, Vlasenkova R, Ghatalia P, Zhou Y, Rainey K, Forman AF, Dunbrack RL Jr, Golemis EA, Hall MJ, Daly MB, Arora S.

Mol Genet Genomic Med. 2019 Mar;7(3):e556. doi: 10.1002/mgg3.556. Epub 2019 Jan 24.

5.

Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).

Nikonova AS, Deneka AY, Kiseleva AA, Korobeynikov V, Gaponova A, Serebriiskii IG, Kopp MC, Hensley HH, Seeger-Nukpezah TN, Somlo S, Proia DA, Golemis EA.

FASEB J. 2018 May;32(5):2735-2746. doi: 10.1096/fj.201700909R. Epub 2018 Jan 10.

6.

RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells.

Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM.

Bio Protoc. 2017;7(15). pii: e2435. doi: 10.21769/BioProtoc.2435. Epub 2017 Aug 5.

7.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

8.

Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.

Gaponova AV, Deneka AY, Beck TN, Liu H, Andrianov G, Nikonova AS, Nicolas E, Einarson MB, Golemis EA, Serebriiskii IG.

Oncotarget. 2017 Mar 21;8(12):19156-19171. doi: 10.18632/oncotarget.13353.

9.

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Oct;15(10):2486-2497. Epub 2016 Aug 9.

10.

Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D, Donahoe PK, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, Golemis EA.

Cell Rep. 2016 Jul 19;16(3):657-71. doi: 10.1016/j.celrep.2016.06.043. Epub 2016 Jul 7.

11.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

12.

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6955-60. doi: 10.1073/pnas.1513616113. Epub 2016 Jun 6.

13.

Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.

Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB.

Oncotarget. 2015 Nov 24;6(37):39614-33. doi: 10.18632/oncotarget.5554.

14.

Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas.

Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Bodian DL, Vockley JG, Zhou Y, Handorf EA, Egleston BL, Andrake MD, Nicolas E, Serebriiskii IG, Yen TJ, Hall MJ, Golemis EA, Enders GH.

Gastroenterology. 2015 Dec;149(7):1872-1883.e9. doi: 10.1053/j.gastro.2015.08.052. Epub 2015 Sep 5.

15.

Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.

Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R.

Oncotarget. 2015 Aug 7;6(22):18863-74.

16.

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA.

Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1.

17.

Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.

Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, Golemis EA, Weiner LM.

Oncogene. 2016 Mar 31;35(13):1643-56. doi: 10.1038/onc.2015.226. Epub 2015 Jul 13.

18.

Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.

Ramirez UD, Nikonova AS, Liu H, Pecherskaya A, Lawrence SH, Serebriiskii IG, Zhou Y, Robinson MK, Einarson MB, Golemis EA, Jaffe EK.

BMC Cancer. 2015 May 28;15:436. doi: 10.1186/s12885-015-1415-6.

19.

Integrating in silico resources to map a signaling network.

Liu H, Beck TN, Golemis EA, Serebriiskii IG.

Methods Mol Biol. 2014;1101:197-245. doi: 10.1007/978-1-62703-721-1_11.

20.

Aurora kinases in head and neck cancer.

Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA.

Lancet Oncol. 2013 Sep;14(10):e425-35. doi: 10.1016/S1470-2045(13)70128-1. Review.

21.

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC.

Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30.

22.

Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.

Seeger-Nukpezah T, Proia DA, Egleston BL, Nikonova AS, Kent T, Cai KQ, Hensley HH, Ying W, Chimmanamada D, Serebriiskii IG, Golemis EA.

Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12786-91. doi: 10.1073/pnas.1301904110. Epub 2013 Jul 15.

23.

DUSP6 regulates drug sensitivity by modulating DNA damage response.

Bagnyukova TV, Restifo D, Beeharry N, Gabitova L, Li T, Serebriiskii IG, Golemis EA, Astsaturov I.

Br J Cancer. 2013 Aug 20;109(4):1063-71. doi: 10.1038/bjc.2013.353. Epub 2013 Jul 9.

24.

Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.

Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I.

Cancer Discov. 2013 Jan;3(1):96-111. doi: 10.1158/2159-8290.CD-12-0031. Epub 2012 Nov 2.

25.

Aurora A kinase (AURKA) in normal and pathological cell division.

Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr, Golemis EA.

Cell Mol Life Sci. 2013 Feb;70(4):661-87. doi: 10.1007/s00018-012-1073-7. Epub 2012 Aug 3. Review.

26.

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA.

Drug Resist Updat. 2011 Dec;14(6):260-79. doi: 10.1016/j.drup.2011.08.002. Epub 2011 Sep 14. Review.

27.

Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I.

Cancer Biol Ther. 2010 Nov 1;10(9):839-53. Epub 2010 Nov 1. Review.

28.

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA.

Sci Signal. 2010 Sep 21;3(140):ra67. doi: 10.1126/scisignal.2001083.

29.

NEDD9 promotes oncogenic signaling in mammary tumor development.

Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA.

Cancer Res. 2009 Sep 15;69(18):7198-206. doi: 10.1158/0008-5472.CAN-09-0795. Epub 2009 Sep 8.

30.

A bacterial/yeast merged two-hybrid system: protocol for bacterial screening.

Serebriiskii IG, Milech N, Golemis EA.

Methods Mol Biol. 2007;408:291-315. doi: 10.1007/978-1-59745-547-3_16.

PMID:
18314589
31.

A bacterial/yeast merged two-hybrid system: protocol for yeast screening with single or parallel baits.

Tikhmyanova NY, Izumchenko EA, Serebriiskii IG, Golemis EA.

Methods Mol Biol. 2007;408:257-90. doi: 10.1007/978-1-59745-547-3_15.

PMID:
18314588
32.

A novel Cas family member, HEPL, regulates FAK and cell spreading.

Singh MK, Dadke D, Nicolas E, Serebriiskii IG, Apostolou S, Canutescu A, Egleston BL, Golemis EA.

Mol Biol Cell. 2008 Apr;19(4):1627-36. doi: 10.1091/mbc.E07-09-0953. Epub 2008 Feb 6.

33.

Selective Raf inhibition in cancer therapy.

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA.

Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. Review. Erratum in: Expert Opin Ther Targets. 2009 Sep;13(9):1135.

34.

A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9.

O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA.

Cancer Res. 2007 Oct 1;67(19):8975-9. Review.

35.

A 1.55 A resolution X-ray crystal structure of HEF2/ERH and insights into its transcriptional and cell-cycle interaction networks.

Jin T, Guo F, Serebriiskii IG, Howard A, Zhang YZ.

Proteins. 2007 Aug 1;68(2):427-37.

PMID:
17444515
36.

A combined yeast/bacteria two-hybrid system: development and evaluation.

Serebriiskii IG, Fang R, Latypova E, Hopkins R, Vinson C, Joung JK, Golemis EA.

Mol Cell Proteomics. 2005 Jun;4(6):819-26. Epub 2005 Mar 20.

37.

Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA.

Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, Pehrson JR, Berger JM, Kaufman PD, Adams PD.

Dev Cell. 2005 Jan;8(1):19-30.

38.

A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system.

Sudomoina M, Latypova E, Favorova OO, Golemis EA, Serebriiskii IG.

BMC Biotechnol. 2004 Apr 29;4:9.

39.

Analysis of protein-protein interactions utilizing dual bait yeast two-hybrid system.

Serebriiskii IG, Kotova E.

Methods Mol Biol. 2004;261:263-96. Review.

PMID:
15064464
40.

Detection of peptides, proteins, and drugs that selectively interact with protein targets.

Serebriiskii IG, Mitina O, Pugacheva EN, Benevolenskaya E, Kotova E, Toby GG, Khazak V, Kaelin WG, Chernoff J, Golemis EA.

Genome Res. 2002 Nov;12(11):1785-91.

41.

KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis.

Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA.

Hum Mol Genet. 2002 Feb 15;11(4):389-96.

PMID:
11854171
42.

Two-hybrid system and false positives. Approaches to detection and elimination.

Serebriiskii IG, Golemis EA.

Methods Mol Biol. 2001;177:123-34. No abstract available.

PMID:
11530601
43.

Analysis of small GTPase signaling pathways using p21-activated kinase mutants that selectively couple to Cdc42.

Reeder MK, Serebriiskii IG, Golemis EA, Chernoff J.

J Biol Chem. 2001 Nov 2;276(44):40606-13. Epub 2001 Aug 20.

44.

Genomic analysis utilizing the yeast two-hybrid system.

Serebriiskii IG, Toby GG, Finley RL Jr, Golemis EA.

Methods Mol Biol. 2001;175:415-54. Review. No abstract available.

PMID:
11462850
45.

Two-hybrid dual bait system to discriminate specificity of protein interactions in small GTPases.

Serebriiskii IG, Mitina OV, Chernoff J, Golemis EA.

Methods Enzymol. 2001;332:277-300. No abstract available.

PMID:
11305104
46.

Redefinition of the yeast two-hybrid system in dialogue with changing priorities in biological research.

Serebriiskii IG, Khazak V, Golemis EA.

Biotechniques. 2001 Mar;30(3):634-6, 638, 640 passim. Review.

47.

Computational and experimental analyses reveal previously undetected coding exons of the KRIT1 (CCM1) gene.

Sahoo T, Goenaga-Diaz E, Serebriiskii IG, Thomas JW, Kotova E, Cuellar JG, Peloquin JM, Golemis E, Beitinjaneh F, Green ED, Johnson EW, Marchuk DA.

Genomics. 2001 Jan 1;71(1):123-6.

PMID:
11161805
48.

LexA-based two-hybrid systems.

Fashena SJ, Serebriiskii IG, Golemis EA.

Methods Enzymol. 2000;328:14-26. No abstract available.

PMID:
11075335
49.

Uses of lacZ to study gene function: evaluation of beta-galactosidase assays employed in the yeast two-hybrid system.

Serebriiskii IG, Golemis EA.

Anal Biochem. 2000 Oct 1;285(1):1-15. Review. No abstract available.

PMID:
10998258
50.

Streamlined yeast colorimetric reporter activity assays using scanners and plate readers.

Serebriiskii IG, Toby GG, Golemis EA.

Biotechniques. 2000 Aug;29(2):278-9, 282-4, 286-8.

Supplemental Content

Loading ...
Support Center